Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease

Table 7 Positive rates of SV2A in APOE ε4 carriers who were negative for other biomarkers

Note: The Youden index was calculated to determine the best cutoff value. Abbreviations: APOE ε4 +/−, APOE ε4 carriers; GFAP(−)-APOE ε4 +/−, serum GFAP-negative patients (≤ 16.6 pg/mL in APOE ε4 +/−); GFAP(+), serum GFAP-positive patients (> 16.6 pg/mL in APOE ε4 +/−); GFAP, glial fibrillary acidic protein; NfL(−)-APOE ε4 +/−, serum NfL-negative patients (≤ 1.1 pg/mL in APOE ε4 +/−); NfL(+), serum NfL-positive patients (> 1.1 pg/mL in APOE ε4 +/−); NfL, neurofilament light; p-tau217(−)-APOE ε4 +/−, serum p-tau217-negative patients (≤ 1.8 pg/mL in APOE ε4 +/−); p-tau217(+), serum p-tau217-positive patients (> 1.8 pg/mL in APOE ε4 +/−); p-tau217, phosphorylated tau; SV2A (+), serum SV2A-positive patients (≤ 4413.00 pg/mL in APOE ε4 +/−); SV2A, synaptic vesicle glycoprotein 2 A

ISSN: 1758-9193